Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer

EGFR and HER-2 are important targets but none of the monoclonal antibodies or small molecule tyrosine kinase inhibitors specific for the HER members has been approved for the treatment of patients with ovarian cancers. In some studies, co-expression of other growth factor receptors has been associat...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Puvanenthiran, Soozana, Essapen, Sharadah, Haagsma, Ben, Bagwan, Izhar, Green, Margaret, Khelwatty, Said Abdullah, Seddon, Alan, Modjtahedi, Helmout
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2018
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5929416/
https://ncbi.nlm.nih.gov/pubmed/29731973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24791
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires